Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Anticuerpos Antinucleares PDF
Anticuerpos Antinucleares PDF
Adams BB, Mutasim DF. The diagnostic value of anti-nuclear antibody testing. International Journal of Dermato-
logy 2000; 39: 887-891. Blackwell Science Ltd.
159
Vol. 4, Nm. 3. Abril 2001
160
Importancia diagnstica de la determinacin de los ANA
Tabla 2
Tipos de ANA y enfermedades asociadas (13)
LE x x x x
ESP x x
TMTC x
DM x
CREST x
CREST, calcinosis, fenmeno de Raynaud, dismotilidad esofgica, esclerodactilia y telangietasias; DM, dermatomiositis; LE, lupus
eritematoso; TMTC, trastorno mixto del tejido conectivo; ESP, esclerosis sistmica progresiva.
Figura 2. Tipos de ANA fluorescente: (a) moteados, (b) homogneos, (c) perifricos (anillo) y (d) nucleolares.
161
Vol. 4, Nm. 3. Abril 2001
100
60
40
0-20%*
20
Figura 3. Prevalencia de
anticuerpos Ro (SSA) en varias
0
LEN Madres de LES de LECS LE con Sndrome LED Esclerosis enfermedades (por inmunodifusin)
nios con comienzo ANA de Sjgren sistmica (2). LED, lupus eritematoso discoide;
LEN tardo negativos LEN, lupus eritematoso cutneo
Diagnstico
subagudo, LES, lupus eritematoso
sistmico. *Vase el intervalo.
162
Importancia diagnstica de la determinacin de los ANA
ARNt-sintetasa y estn presentes en algunos pacientes cin diagnstica de los pacientes con TTC. El cono-
con polimiositis y dermatomiositis (41) (tabla 3). cimiento del valor predictivo de la prueba de ANA
y la importancia de su ttulo y tipo es fundamental
para la evaluacin del resultado de esta prueba.
Conclusiones Adems, algunos anticuerpos especficos se relacio-
nan con algunas enfermedades y la presencia de
La deteccin de los anticuerpos antinucleares estos anticuerpos tiene consecuencias muy impor-
aporta una informacin muy valiosa para la evalua- tantes.
Bibliografa
1. Fernndez-Madrid F, Mattioli M. Anti- antibodies in an unselected pregnancy 23. Thompson D, Juby A, Davis P. The
nuclear antibodies (ANA): immunologic population. Gynecol Obstet Invest clinical significance of autoantibody
and clinical significance. Semin Arthr 1992; 33: 21-25. profiles in patients with systemic lupus
Rheum 1976; VI: 83-124. erythematosus. Lupus 1993; 2: 15-19.
13. Sontheimer RD, McCauliffe DP,
2. Provost TT, Watson R. Antinuclear Zappi E, Targoff I. Antinuclear antibo- 24. Falanga V, Medsger TA, Reichlin M.
antibodies in systemic lupus erythema- dies: clinical correlations and biologic Antinuclear and antisingle-stranded
tosus. In: Norris DA, ed. Immune Me- significance. Adv Dermatol 1991; 7: 3- DNA antibodies in morphea and gene-
chanisms in Cutaneous Disease. New 52. ralized morphea. Arch Dermatol 1987;
York: Marcel Dekker, 1989: 333-357. 123: 350-353.
14. Tan EM, Feltkamp TEW, Smolen JS,
3. Cook L. New methods for detection et al. Range of antinuclear antibodies 25. Buskila D, Berezin M, Gur H, et al.
of anti-nuclear antibodies. Clin Immu- in healthy individuals. Arthr Rheum Autoantibody profile in the sera of women
nol Immunopathol 1998; 88: 211-220. 1997; 40: 1601-1611. with hyperprolactinemia. J Autoimmun
1995; 8: 415-424.
4. Saitta MR, Keene JD. Molecular 15. Slater CA, Davis RB, Shmerling RH.
biology of nuclear antigens. Rheum Antinuclear antibody testing. A study of 26. Gripenberg M, Helve T, Kurki P.
Dis Clin N Am 1992; 18: 283-310. clinical utility. Arch Intern Med 1996; 156: Profiles of antibodies to histones, DNA
1421-1425. and IgG in patients with systemic
5. Hahn BH. Antibodies to DNA. N rheumatic diseases determined by ELI-
Engl J Med 1998; 338: 1359-1368. 16. Malleson PN, Sailer M, Mackinnon SA. J Rheumatol 1985; 12: 934-939.
MJ. Usefulness of antinuclear antibody
6. Carey JL. Enzyme immunoassays for testing to screen for rheumatic dise- 27. Rubin RL, Waga S. Antihistone an-
antinuclear antibodies. Clin Lab Med ases. Arch Dis Child 1997; 77: 299- tibodies in systemic lupus erythemato-
1997; 17: 355-365. 304. sus. J Rheumatol 1987; 14 (Suppl 13):
118-126.
7. Emlen W, ONeill L. Clinical signifi- 17. Bernstein RM, Steigerwald JC, Tan
cance of antinuclear antibodies; compa- EM. Association of antinuclear and an- 28. Grossman L, Barland P. Histone
rison of detection with immunofluo- tinuclear antibodies in progressive sys- reactivity of drug-induced antinuclear
rescence and enzyme-linked immu- temic sclerosis. Clin Exp Immunol antibodies. Arthr Rheum 1981; 24:
nosorbent assays. Arthr Rheum 1997; 1982; 48: 43-51. 927-931.
40: 1612-1618.
18. Moder KG. Use and interpretation 29. Provost TT, Watson R, Simmons-
8. Jaskowski TD, Schroder C, Martins of rheumatologic tests: a guide for cli- OBrien E. Significance of the anti-Ro
TB, et al. Screening for antinuclear an- nicians. Mayo Clin Proc 1996; 71: (SS-A) antibody in evaluation of pa-
tibodies by enzyme immunoassay. Am 391-396. tients with cutaneous manifestations of
J Clin Pathol 1996; 105: 468-473. a connective tissue disease. J Am Acad
19. Fritzler MJ. Antinuclear antibodies Dermatol 1996; 35: 147-169.
9. Ward MM. Laboratory testing for in the investigation of rheumatic disea-
systemic rheumatic diseases. Postgrad ses. Bull Rheum Dis 1985; 35: 1-10. 30. Simmons-OBrien E, Chen S, Wat-
Med 1998; 103: 93-100. son R, et al. One hundred anti-Ro (SS-
20. Evans J. Antinuclear antibody tes- A) antibody positive patients: a royear
10. Xavier RM, Yamauchi Y, Nakamura ting in systemic autoimmune disease. follow-up. Medicine 1995; 74: 109-
M, et al. Antinuclear antibodies in he- Clin Chest Med 1998; 19: 613-625. 130.
althy aging people: a prospective study.
Mech Ageing Dev 1995; 78: 145-154. 21. Jansen EM, Deng J-S, Beutner EH, 31. Field M, Williams DG, Charles P,
et al. Comparison of commercial kits Maini RN. Specificity of anti-Sm anti-
11. Kiuttu J, Hartikainen AL, Makitalo for the detection of anti-nDNA antibo- bodies by ELISA for systemic lupus
R, Ruuska P. The outcome of preg- dies using Crithidia luciliae. Am J Clin erythematosus: increased sensitivity of
nancy in antinuclear antibody-positive Pathol 1987; 87: 461-469. detection using purified peptide anti-
women. Gynecol Obstet Invest 1994; gens. Ann Rheum Dis 1988; 47: 820-
37: 160-163. 22. Lange A. Evaluation of the simultane- 825.
ous estimation of anti-dsDNA and anti-
12. Kiuttu J, Hartikainen-Sorri AL, Ma- ssDNA antibodies for clinical purposes. 32. Hamburger M, Hodes S, Barland P.
kitalo R. Occurrence of antinuclear Clin Exp Immunol 1978; 31: 472-481. The incidence and clinical significan-
163
Vol. 4, Nm. 3. Abril 2001 sumario
164